Good day, welcome to the Medicover second quarter 2023 results presentation. At this time, all participants are in listening only mode. After the speaker's presentation, there will be a question- and- answer session, to ask questions during the session, you will need to press star one one on your telephone keypad, you should hear an automated message advising you that your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand you over to your speaker of today, Fredrik Rågmark. Please go ahead. Thank you. Good morning, everyone. Welcome to our second quarter 2023 results pre-presentation. We have headlined our first slide, strong organic growth, although still difficult macroeconomic environment. I think that summarized very well the environment we're in, still high inflation, cost pressures, et cetera, et cetera. Despite that, I think we deliver a very solid, robust set of numbers, fundamentally underlying good, strong organic growth, overall 12.9%. Neutralizing for the impact of the still quite significant COVID quarter last year around, we take up to 22% organic growth. Again, a good solid number, of that, just below 10 percentage points represent price, illustrating the impact of the quite significant efforts the team has done on price adjustments over the past year. To, you know, point your attention to the fact that if we annualize the growth in the quarter, we put on more than EUR 350 million of additional revenue since over the last 12 months, and the vast majority of that is organic growth. I think that is a good sort of a bookmark in terms of us being well underway in terms of the new three-year financial targets. We're just six months into that new three -year period, but despite that, I think we have, we've started that period in a very, in a very good and strong way. Healthcare Services, a very strong quarter, solid growth and margins improving on the back of price growth, gradually maturing units, and just scale. You know, putting more customers through our fixed cost infrastructure. Equally, Diagnostic Services, you know, optically, the first look, it may look sort of flattish, and that's obviously with COVID unwinding. As we'll take you through, when you look into the numbers, it's actually really good, underlying solid growth, volume-wise and mix-wise, and also price, although held back obviously by Germany being big in this division. We just recently inaugurated a new big 200 bed multi-specialty hospital in Bucharest. In fact, you know, perhaps that more anecdotal than anything, but it's the first a hospital of its size and specialization to open in Bucharest in many decades. That's gonna be an important piece in terms of driving our Romanian business. Importantly, I make a statement at the end of my CEO comment, is that we expect to see continued improved performance during the second half of this year and also into 2024. That's really on the back of the same drivers that we have seen impacting the results this quarter. A bit more specific, the revenue here for the second quarter, then just short of EUR 425 million. Run rate-wise, then some EUR 1.7 billion annualized. That's up 17.2%, of which organic 12.9%. Again, I think that's a very solid result, not to forget all the COVID-19 revenue that we replaced, and in addition to that, has put on quite a bit of more revenue. Excluding for that point made before 22% organic growth, excluding COVID, acquired revenue in this EUR 25 million, and now fee-for-service is up to 58% of the total group. On the pie chart, perhaps just to bring your attention to one data point, and that is actually for, I think it's the first time for quite some quarters where Poland is actually gaining a proportional share. We see that's up to 48% of our overall revenue base, and that's on the back of growing 30% in the quarter, which is quite an outstanding number. There's some foreign exchange gains in there, et cetera, but nevertheless, that's quite an outstanding number. Otherwise, I think the graphs and pie chart on this page will speak for themselves. Moving on to margins. Strong development despite falloff of COVID-19 now. The second quarter last year, we still had EUR 28 million revenue COVID, I believe. That's really the it's tapering off quite significantly than in the comparative quarters, Q3 and Q4 last year. This is in a way, the last quarter where we have really tough comps from COVID-19. And I think you can see that very well in the. in the bar chart to the right where obviously the blue is the sort of underlying, and you have that light gray being the EBITDA top up, which you can see sort of topped off in the final quarter 2021, but still was not insignificant for the first half last year. I think that's quite a good illustration of what's happening underlying. Just north of EUR 58 million EBITDA, up 10%, 13.7% margin. Again, if we adjust that for COVID, you know, we increased margins 120 basis points to 13.7%. Adjusted EBITDA just north of EUR 61 million, and adjusted EBITDAaL at EUR 36.7, 8.6% down from prior 9.6%. EBIT, just above EUR 13 million. Also important to point out, yeah, we sort of comment on that in every quarter, but it's important to remind you that we, you know, we do have very strong cash generation. That's part of the business model we operate. That was the same this quarter, so good, solid, strong cash flow, which is good to see. Moving on to Healthcare Services. Revenue then EUR 292.5 million, so just short of EUR 1.2 billion run rate revenue in Healthcare Services. Quite an impressive number, up 33%, of which organic 22%. In this 22% organic growth, price is about 12 percentage points, 10% being, you know, volume and a bit of mix. Good, solid underlying volume and importantly, price growth. This is obviously a key measure through which we have addressed and do address the still ongoing cost inflation in pretty much all our countries, but obviously Poland being by far the largest and most important one. EUR 25 million, so you see most, basically all of the acquired revenue in the group sits here. Fee-for-service grew strongly, so up 28%, significant, no COVID-19 impacts on that side. Just a good, solid performance and demand levels, and we see that throughout. I mentioned before the new hospital in Bucharest that opened, and we have three major openings scheduled in India during the second half of the year. Although we say that we have slowed down the investment pace to more historic levels, Joe will talk more about that later on, that does not mean in any way that we have stopped investing. We have more brought it back to more historic normalized levels. We continue to see good member growth, 20,000 new members in the quarter, 7.5% up. Just a little bit north of 1.7 million members in the corporate paid business. Now, volume growth, some maturing and price hardening led to good sort of flow-through for Healthcare Services. EBITDA just short of EUR 45 million, up more than 50% versus last year, at 15.3%, 180 basis points or so improvement. Good to see that. Let's not forget that we still have a lot of immature units, not the least, the large one we just opened in Bucharest. EBITDAaL of EUR 26.8 million, again, a good solid growth from prior years. You know, the factors driving this I have already commented on. If we flip to Diagnostic Services, revenue EUR 138.1 million, that's an organic reduction of just 0.4 percentage points. You see that we had EUR 800,000 from COVID revenue this quarter versus EUR 27 million last year. Comparing, underlying like for like, the organic growth in this division, excluding COVID, was 21%, of which price represents 5 percentage points. That 16% is then largely volume driven, but a couple of percentage points of mix in there as well. You can see if the price represents 5 percentage points here. I talked you through before that we had 12 percentage points in Healthcare Services. Now, you recall, as you see there at the bottom, that Germany is basically now it's 48%, I believe, of the division where we had no price movement. Five percentage points is quite a figure to be expected relative to the movements we have seen in the other division, i.e., price growth outside Germany has worked real well, but we still, you know, wait to see something in that respect in Germany. Ukraine continues to perform just outstandingly, considering the circumstances. We say every quarter, we take off our hats for the colleagues in Ukraine, and we continue to do so. Test volume represent now approximately 80% of normalized levels, so quite an outstanding achievement. The fee-for-service here represented 70%, and that was basically flat versus the prior year. Moving then on to how has that impacted margins in Diagnostics, I think they performed quite well under the circumstances. Beat out just north of EUR 20 million, 14.7%, or be quite a big contraction from prior year with the COVID-19 earnings. Excluding COVID-19, we were at 14.7%. That's down 40 basis points from prior year, which is driven solely by the German situation. We're actually compensating that significantly much more outside of Germany and then being slightly held back for the time being in Germany. A EBITDAaL of EUR 14 million is the approximate 10% margin down from just north of 15% last year. You see that flow straight through the P&L exactly in the same way. I think important to point out here is the solid underlying volume growth and price growth in well, volume growth across the division, really, and then price growth outside Germany. We make the point here, still no price adjustments on the horizon in Germany, and that is the situation, and we will see when that comes. I think with that summary, I will hand over to Joe and then come back to answer your questions after Joe's session. Thank you, Fredrik. Interest rates, we're in an interest rate environment which has increased, we expect to see our interest rates costs go up. In terms of lease liability interest, this is more of a fixed nature because this is the inception of the lease. That has increased with the in line with the increase in the lease liabilities, but there's not been no rate impact in respect of on that. Other interest costs, which is relates to real debt, if you like, that's round about doubled. Our total interest charge EUR 11.5 million. In terms of the implied interest rates, it's gone up slightly with the new leases and indexation for lease liabilities on the real debt, we've pretty much sort of doubled in terms of the effective interest rate cost that for the cost of the debt. Approximately half of the debt is fixed interest rate and approximately the rest is floating rates. Average maturity good. The only maturity we've got on our horizon is 2024, with small rollover in our German Schuldschein debts in the second half of the year. Really, we need to look through to 2025 before we see our first real maturities coming up. In terms of the indebtedness levels, they've stayed pretty stable since the end of 2022. Since the end of 2022, loans payable, net balances have increased around about EUR 12 million, very benign. In terms of the indebtedness levels ratios, as reported, that has increased, 3.2x-3.5x from the end of the year. We will see that now trend down over the second half of the year. It's not about the debt levels, 'cause as you can see, the debt levels have stayed pretty static. It's about the fallout of COVID contribution and the replacing of that with our underlying business. As those numbers increase on the second half of the year, we'll see the debt levels trend down. The indebtedness levels trend down. In terms of cash flow, strong cash flow for the first half, we've done EUR 105 million net operational cash flow. If we look at that in terms of a free cash flow basis, we've invested some EUR 53.9 million cash in terms of capital spending, that leaves us with about EUR 51 million in terms of free cash flows. A strong number there performing as we reduced our capital investment pace to a level which is commensurate with where we've been in the past. If we look back to prior year on that sort of free cash flow basis, we were EUR 73.6 million for the first half in terms of cash flows, and we spent EUR 67.9 million in terms of capital spending, much higher pace back in 2022, so it's EUR 5.7 million free cash flow on a comparable basis. That's just you sort of an idea in terms of the business cash generation, which we're generating. I move on in terms of lease liabilities, those have slightly increased there, so we're up about EUR 13 million. The largest movement is in terms of lease extensions and indexation, EUR 45 million. About EUR 25 million of that is actually new leases or extensions. EUR 20 million is indexation impacts, which really come through now, rather than we're seeing those come through in 2022 as a trailing impact. Our equity has increased slightly. We've gone from EUR 472 million to EUR 485 million. The largest movement on there has been our translation impact with the increasing strength of the Polish złoty and our large exposure in terms of our balance sheet on Polish złoty assets. We've seen a large movement in terms of the translation of our balance sheets. Just coming back in terms of our capital investment, so Q2, that was EUR 24.3 million, EUR 53.9 million for the first six months. A little bit of that coming over from prior year, where we were investing at a higher pace. Our Healthcare Services, finishing off some of the assets which we had running on there, particularly the hospital in Bucharest. EUR 39.7 million for the six months and EUR 14.2 million for our Diagnostic Services. If we look at where we're running, it was at 5.7% of revenue in Q2, 6.4% for the first half. If we look through for the year end, it's gonna be sort of similar levels overall for the full year. That's down from our 9.9% that we invested in for the full year 2022. It gives you an idea that we are slowing down our organic deployment of capital, but that's still in line with where we were, sort of in prior years. We had 7.6% back in 2021, and the total amount is gonna be north of EUR 100 million that we deploy. We're not sort of slowing it down historically, we're slowing it down from sequentially, from our very high levels in 2022. About a third of the amount that we've invested has gone into hospital facilities in the first half, so Romania, India, and Poland. Long-lived assets, infrastructure assets, which will be earning us cash for 20, 30 years. In terms of the financial targets, we are well on our way in terms of meeting our revenue targets. You can see there, if you annualize our revenues for the quarter, then you can see we've still got quite a chunky number in terms of to fill that EUR 2.2 billion target. I think you can be fairly confident that we will be able to deliver on that. In terms of our EBITDA targets, again, we have a way to go in terms of getting to that EUR 350 million. Again, as you can see with the sequential improvement in terms of margins, which we expect to see, a continuation of that development through the second half this year and then into 2024. Again, both with the size and increase of the business, and then also with margin development, we expect to be on track to deliver on those targets as well. We are up at our leverage levels 3.5x. We're quite happy to be there. That means we're using our balance sheet. The cash generation, as I alluded to earlier, you can see in terms of we can manage our debt levels quite well, but changing our pace of deployment of new capital. We're in a good shape to deliver on our 2025 targets. All right. Thank you, Joe. I think with that, we are happy to take any questions you may wanna have for us. Thank you. As a reminder, to ask questions, you'll need to press star one one on your telephone keypad and wait for your name to be announced. To withdraw a question, please press star one one again. We're now gonna go to our first question. Our first question is coming from Kristofer Liljeberg from Carnegie Investment Bank. Your line is open, please go ahead. Thank you, and good morning. I have three questions. First, the better margin you see in the healthcare business here, again, is that only driven by better utilization, or is it something else also helping? My second question relates to India. It seems growth is slowing down there a bit sequentially, or is this just an FX impact? If you could explain that. Finally, on the margin for the Diagnostic business, is there anything you could do there to support margins, given the large exposure you have to Germany? Thank you. If I take the first one, Joe. The better margin in Healthcare Services, I would you know, I gave you three points there, Kristofer, and I think of the three, probably the most important one is the first one. You do have a quite significant price impact. I mean, you can work that backwards. I gave you the—i f you look at the organics starting point last quarter, around at 12%, you see the amount of money we generated in Healthcare Services from price growth and which is the largest driver of margin improvement there. The maturing impact is relatively limited, not because we are not maturing, but because we're also putting on additional new units. You have a general volume impact. The first one is by far the biggest driver of that, of what you see. I'll take the third one, and then I give the second one to Joe. Sorry, could I just. Yeah? Could I just follow up on that? Sure. I guess you stated in the report that you expect to continue to increase prices. At the same time, there also seems to have been some customer loss due to the price increases. How would you view the price elasticity here? Would you expect that if you continue to increase prices here, it would be more difficult to grow volumes at the same time? Yeah, I mean, you know, there's inevitably always gonna be a trade-off one way or the other, Kristofer, you know, that, your, the question is correct. I think the sort of answer to give is that relatively speaking, it will become more difficult to negotiate price increases, you know, the more you have historically raised prices, no doubt about that. On the other hand, you know, the change in pace of inflation is also coming down. I think the majority of price compensation for cost growth is probably behind us, but there's still some to come. That's one piece of the answer. The second piece of the answer is that, you know, different customers will inevitably have different kinds of price elasticity. You know, when you operate the network, which is, in terms of the corporate paid business, that, you know, that's largely utilized. You run that asset base pretty much fully utilized, so to speak. If you replace the customer with where you can't negotiate the price to an appropriate level, as long as you replace that customer with someone with, you know, with a better price, that's fine somehow. We're not nervous at this point in time, that you will see significant sort of volume drop due to this. What we have commented on, I think, in every quarter, so I can make that comment in relationship to this question as well. You know, we haven't really seen any weakening in the sort of corporate demand. Everyone talks about this much weaker economy, and I mean, there's a lot of signals that the economy will weaken. You know, that has not been seen at all in Poland yet. Somehow, I think the economy is actually performing very well. You know, at some stage you may see a weakening of the economy, which would then knock on to sort of demand levels in the corporate business. We haven't seen that yet, which I think is quite noticeable. Perhaps I'll just do that then. Was that fine? Did I answer your question, Kristofer? Yeah, yeah. Excellent. Thank you. And then, on... Oh, no, go ahead, Joe. In India, Kristofer, I think you're probably a little bit used to sort of like maybe the spectacular growth rates that we get coming out of Poland, because we still have year-on-year, very strong growth in India. We come out of the quieter periods in the second quarter. The start of the second quarter is normally quieter, which, and also the first quarter is quieter for Indian business seasonally. We're still up some 13% in our Indian hospitals business in euro terms. For the quarter, there's no real impact in terms of exchange rates year-on-year. For the first half, there is quite a significant exchange rate weakening for the average rate that we use. It's INR 88.9 per euro for the average f or this time around. I t was INR 83.3 per euro last time around. On the first half numbers, it might be that you've got a bit of foreign exchange weakness, but not on the Q2 numbers themselves. We're quite happy with the development. We're not particularly concerned in any respect. We've got four new units in there, less than 12 months old. One is positive in the quarter, three are still negative. They are obviously quite large units, so the negative contribution is quite large. You know, some of them are still relatively new, so they've got to get all the doctors in there, all the referral networks, get all the accreditations, get all the insurance companies signed up. There's a lot of work in terms of building up the revenue stream for new hospitals. It's all going fine there. We're not worried about that. It's on track. 13% growth year-on-year is pretty good, I'd say. Thank you. Your DX margin question, Kristofer. You know, as long as you can't impact the price, you can impact your cost level. Basically, in terms of how you your network optimization, you know, in which labs do you run, which kind of tests, and obviously, your basic fixed cost structure, which is largely, you know, headcount. Making sure that you run everything as cost efficiently as is possible, that's really the key lever you have, as long as, you know, a price is not addressed, you know. There we also got a comment here on the web I see here, which, so I can take that right away, where we make a mention in the running text of the report that we expectation of reimbursement rate increases in Germany are building up. You know, the reference to that comment should really be read in terms of that, you know, there's a lot of pressure across the industry because, you can imagine with the cost inflation, the smaller you are as an operator, the more you're exposed to these factors. So the smaller you are, the more difficult it is to compensate yourself, what I just talked about, to sort of cost optimize. Obviously, still in Germany, a very large part of the healthcare sector, including diagnostics, would be relatively small operators. That's the background to that statement, so, but, you know, as long as nothing has happened, nothing has happened. It's more that the sort of, call it, industry expectations are indeed, building up. We will see where that comes out. Thank you very much. Thank you very much for your question. We're now gonna move on to our next question. Just transferring now. Our next question is coming from Mattias Vadsten from SEB. Your line is open. Please go ahead. Hi. My first question was also on the same question on India, I guess I missed a little bit. Did you give the year-on-year growth in constant exchange rates there, Joe? Mattias, hi. No, I didn't. I gave it in euro terms. In euro terms, it's 13%, 13% up, 13.4% up year-on-year for the quarter, and for the six months, it's up 15.8% in euro terms. As I said, in terms for the Q2, the number I just gave you, that's pretty much what it would be in constant currency as well. And it would be a higher number for the six months. We've got quite an exchange rate movement against us in terms of currency conversion for the six months. Okay, perfect. Do you expect, you know, that this rate year-on-year will increase or be higher towards the second half and into next year, given the new sort of facilities that you have and so on? Well, we have new facilities opening in the second half, but they're not gonna contribute significantly in terms of revenues, 'cause they'll be, you know, new opened over the six months, and maybe even one of them will go into next year. We've got only got one which will be opening shortly. The women and child one in Hyderabad. The others will be well into the second half. I don't think we're gonna see very much movement in respect to them, and it's just about otherwise splitting up the capacity that we have open and running now. We will see sequentially reasonable growth. you know, you know, there's nothing spectacularly different, I think, from our Polish or our other high growth markets in terms of India, we see it as quite similar. I think what you're seeing in terms of, you know, the fantastic growth that we see coming out of the Polish assets is just again, the size and the scale of what we've done. Remember, the Polish assets are also supported by inorganic activity. whereas all the Indian stuff is organic. Okay. Thank you. Next question on margins. Historically, I'm referring to before the pandemic, you expanded the margin by a percentage point or so into Q3 from Q2. Could you know, not give an exact figure, but help us understand the drivers into Q3? If you know, could expand margins maybe more quarter-over-quarter than what we've seen in the past, you know, referring to this percentage point expansion into Q3 from Q2 as a seasonal pattern. That's the next one. You've got seasonality going in two different directions for the businesses. Well, three different, maybe I'll put it into three different business boxes, if you like. You've got diagnostics, where you've got lower volumes coming through, you know very well that it's very dependent in terms of volumes. You get a small drop-off in volumes, you see it impacting in terms of the margin contribution, and likewise, the other way around. We've got lower volumes in the Q3, in the summer months for the diagnostics, so that goes down. In terms of the employer paid and funded business, we see that going up as we get less utilization in the summer. We get less demand for our services then. We see a higher contribution in the third quarter, which comes through. Then you've got the sort of new business areas, if you like, that we've developed since in the last few years, which is the sort of hospital inpatient type of activities, and they're much also driven by activity. India is going the other direction to Europe, so we've seen more demand in the summer months, and less in the winter months, the northern hemisphere winter months. We see it the other way around in Europe. We get the... You see it's raining very heavily in India. You get a lot of, you got a lot of dengue, you get a lot of malaria and things like that, infectious diseases which come in, so you get admissions on those. Those gives you a good, a good demand-based level as well. Those are the sort of factors driving it. We're gonna see in terms of our margin development, we're gonna see, as we've invested a lot of money over 2022, as we repeat time and time again, we've done a lot of inorganic expansion as well, where we expect to take certain synergies out as we integrate those into our network. A lot of investments that we developed over a period of time, over several years, which start to come to fruition. We're seeing the impact in terms of the margin increase driven by the utilization of those investments. As we sequentially add the capacity utilization into those assets, we see the contribution flow through, and that flows all the way through to the bottom line, because, you know, the marginal cost in terms of adding that or servicing that extra business is very small. That's what we'll see sequentially, quarter-on-quarter, as we go through, as we continue to bring in that. There'll be ups and downs due to seasonality, but we're gonna see that through to the end of the year. We're gonna see that through 2024. That will impact in terms of our net numbers, our net profit, the other profit metrics we use, and also then in terms of the return on the invested capital that we've got, which we've deployed a lot of. That's we've expanded enormously on the balance sheet, we've expanded enormously in terms of the capacity. Our job now and what we're doing sequentially, quarter on quarter, is putting more capacity utilization into those assets, and that will go up over time. We will see that trend up over the second half. We'll see that trend up over 2024. Okay, good. I mean, net-net, quarter-over-quarter, would you say that the seasonality help into Q3 is more accentuated today versus, you know, years before the pandemic? You know, less diagnostics today, more India, for instance. No, I would say it's got more less transparent. It used to be quite simple because I had two businesses which were about half and half. Now, I've got, as I said, I've got sort of three or four different dynamics playing around in terms of, in terms of the seasonality. One moves up slightly or differently with one market or another one. you know, we see more people going back to Ukraine for the summer. Families and things like that. You know, that could well drive demand there in the summer, which wouldn't normally be there. You have too many different factors, Mattias, for me really to be able to give you a good steer. Good. Then on, cash flows, I see it's quite clear, and I appreciate the comments, but I see it's built some working capital in Q2. If you could, just remind us on how to think about the Q3 and, you know, to give us some color there on how to think about it. You look at the first half, we had what? About 6.4% in terms of revenues, 70% growth CapEx, 30% maintenance. You know, if you look through for the full year on those sort of like levels, then you're probably not gonna be far off wrong. We'll be north of EUR 100 million in terms of total amount of capital that we spend, maybe up around about EUR 110 million, something like that. Sorry, I was referring to working capital, sorry. Oh, working capital. Yeah. No, it's good. Ah. It's, you know, you can look at where we are now and/or in the last couple of quarters and few quarters and project that forward, that's gonna be fine. Working capital is relatively benign for us. You know, we have a lot of business that pays us as we go. You know, working capital is not really an issue for us at all. Good. The last one from me is, you know, genetics, and if you could talk about, you know, the momentum in that business and, how you see it, you know, develop here in Q2 and for the remainder of the year. Yeah. You know, we have a continued good development in the call it sort of core NIPT market in Germany. You recall, we got reimbursement from basically a year ago there, July last year. That, that, you know, that is moving well. We are continuing the what we call the tech transfer build-out. The same thing as I have explained, I think, several times, where we initially did a tech transfer from the NIPD Genetics entity into our Munich genetic lab, that we have operated for a number of years ourselves. That same tech transfer model is then applied to other companies, labs, globally. I believe that the latest one that was actioned or commissioned here is a larger lab in Japan during the second quarter. That is moving quite nicely. In general, and we also have some international contracts that have been won, not of any great significance as for this current quarter, but where we bring samples into Munich, and they will start to be more impactful for the second half and certainly into 2024. In general, a pretty good outlook, Mattias. Certainly, not less than what we would have expected in terms of planning. Perfect. Thanks so much. Thank you very much for your questions. We're now gonna move on to our next question. Just transferring now. Our next question is coming from Klas Palin, from Erik Penser Bank. Your line is open. Please go ahead. Thank you so much. Thanks for taking my questions. My first question will be, you indicated in the report that, you expect salaries to increase in the second half, and maybe if you could give some sort of indication, what kind of size of salary increase that you expect, perhaps if there are in any particular market that you see a higher wage pressure during the second half? My second question is about the newly opened hospital in Bucharest, and you seem to have got a good media attention, and haven't been that many hospitals open in many years, as you mentioned. Do you see good patient inflow, and maybe if you could comment anything about what's your expectations for the coming 12-24 months? Hi, Klas. Joe here. Salaries, yes, I mean, we've just got that general background of salary pressure in terms of the full employment market in our eastern countries, and also we see it in Germany as well. it's just that general background, but more particularly, we have also then the increase in Poland in terms of the public healthcare sector. We have mandated increases in the minimum wage, which then impacts us as well, and healthcare workers. That's really part of the political backdrop in terms of the elections coming up in the autumn in Poland. The good news in respect to that is that we also then have our, where we have direct contracts with the National Health Fund. They will be indexed in July as well. We'll see the impact coming through in terms of those salary increases reflected directly in there. The public system is making sure that the money is there to pay for those salary increases. That sort of gets passed through straight away. In terms of our other businesses, it's sort of like what we expect to have anyway. We've got our medical inflation is always running at a high level because there's a shortage in terms of medical workers. We're constantly seeing, you know, salary increases as we bring in new people into the business to service the demand in that element as well. That's taken into account in terms of our pricing on new business, and then also in terms of our indexation, which we're constantly working on with our corporate and privately paid business. I don't see any pressure or issue for us in terms of addressing those salary increases. Maybe Fredrik, you talked about this? Bucharest, we had a good attendance when we had the opening. In fact, I was actually back here last week, so I had a little Romania tour. I was in Bucharest visiting the new hospital. I was up in Oradea, visiting our Pelican Hospital, where we time flies now. That was in the middle of or just as COVID hit, I think we commissioned a new wing there at the Pelican Hospital with about additional 100 beds, and that's all filled up, looks nice. I went to Cluj, which is the second city of size in Romania, after Bucharest, where we have our Polisano Hospital, which is a big facility. As we, I believe, allude to in the report here, we are very positive in terms of having good extensions on our, and I said, Joe said, I said Polisano, sorry, I mean Polaris, excuse that. Polisano is something else in Romania, a business that we don't own, so I correct myself to Polaris. We have good extensions money-wise. Joe talked about NFZ indexing in Poland from July. Likewise, we have good increases in our publicly funded contracts for the second half of 2023 in Romania, which is particularly important actually in that country, because we have this legislation in Romania that some of you are aware of, where you can coordinate payments between the public reimbursement and private pay. Actually to drive your private pay business, it's really important to have enough of public money allocated. That's a really important element to drive a growth in our Romanian hospital business. I think when I was there last week, Klas, I think we had 24 or 25 admissions. That may not sound so terribly much with 200 beds, but, you know, it just opened, and it's in the middle of the summer, so we will clearly have a not insignificant drag for a few quarters from that facility. I don't think one can underestimate the importance of that new flagship hospital in Bucharest for us to drive both growth and competitive positioning in the Bucharest market. I'm, you know, I'm very happy actually, with that. you know, we wanna see that obviously in the same way as with other facilities, increase its utilization levels. It's fair to say we're quite confident on that given the increase in funding we have just received. Okay. And also a question in Romania, if you could comment how the subscription business develops? Actually, " very well" is the short answer. Okay. Sequentially, we have grown our membership base, plus we've been able to push through price growth. You know, we were later off the block, so to speak, in Romania, to push price growth than we were in Poland. And that was partly because the inflationary impact hitting us also came later in Romania than it did in Poland. But over the past couple of quarters, we have seen both good volume growth in terms of members and increasingly price growth. That's that box you can tick, Klas. Okay, perfect. Thank you so much. Thank you for your question. There's no more questions in the queue, at this time. As a reminder, if you want to ask a question, please press star one one on your telephone keypad. While there's no more questions at this point, I'm gonna hand you back to Fredrik Rågmark. Hi. Hello. We had 1 question in terms of in terms of through the chat with David, from Poland. You were asking about the P&L impact in terms of pre-opening costs and new M&A on EBITDA. You ask, is it higher or lower than EUR 1 million net in 1 Q? Yeah, definitely higher. We, you know, got something like about 30 new BDPs we've got in the Diagnostic Services side. Those are relatively smaller because they turn profitable quite quickly. We've got something about nine or more dental units. We've got two IVF clinics. We've got the hospital in Bucharest that's now just opened, plus we've got the three immature units in India, which are still loss-making. In terms of on a net contribution line, in terms of those new units, you know, it's a significant number. We put a lot of money into new units, and because the scale of the investment we did over 2022, that's much higher, you know, if you did to compare back to Q2, 2022. We take a lot of negative numbers, negative contribution in our numbers. That just goes back to what I was saying before about how we improve the margin and how we improve the net line is in terms of getting capacity in, filling up, reducing the losses, turning those into profits, and then maturing those units. That's what we've done always. Just the scale of what we do is much larger at the moment because the scale of what we did in terms of the deployment of organic and inorganic capital spending back in the last 18 months. I think that probably concludes the question. We have one more question from James Vane-Tempest. All right. Okay. Go ahead, James. I'm just gonna transfer him now. The next question is coming from James Vane-Tempest from Jefferies International. Your line is open. Please go ahead now. Hi, good morning. Thanks for taking my questions. Just got one left, actually, and that is, just on Germany. I mean, you say how there's no price adjustments on the horizon. Can you help us sort of understand how much of a drag that is to the business, and how much, or how many levers you've got to essentially, mitigate that impact, and when you potentially see the environment becoming more favorable? Thank you. Maybe we do that together. Maybe I'll just start off maybe a little bit in terms of some of the sort of background aspects of it. You know, we've got a strong inflation environment in terms of cost of labor, partly driven by a lack of labor. Then also, you know, the asking salaries are going up as well. We have now in Q2, the crisis payment, which the German government put in place, which is basically a tax-free bonus type payment that can be paid to employees in April. Obviously we partook in that. That's supposed to compensate for some of the pressures in terms of in lieu of salary increases. We have 1.5 million EUR that we expensed through the P&L account on the Diagnostic Services side in Germany in respect to that, in lieu of salary increases for the year. that helps us to sort of mitigate the sort of salary pressures. We may well see salary pressures building up again next year. Maybe the German government has a similar type thing next year. that impacts us directly in this quarter in terms of reported results, but has an impact, a benefit over the whole year. that's the sort of salary part of what it is, but obviously, rents and property costs are sort of like, you know, have moved up in terms of indexation. We have a lot of fixed contracts with our suppliers in terms of supply costs, and those are multi-year. We entered into some of those just before the sort of crisis entered up in terms of renewals, some of those. We've got a few years in terms of to benefit from those. On the whole reimbursement side, both for the privately paid, privately insured and the publicly insured, we've seen no movement in terms of reimbursement rates. Remember, this is a marginal business, so if we put on marginal extra additional volumes, the contribution from that is very strong. We've got one side, which is where we are growing in terms of the underlying business, ex-COVID. That helps to mitigate against us. The other factor is just in terms of how we automate the processes that we're doing and that being that to try and mitigate that labor cost. We've got a new plant in terms of microbiology. We've got other work going on in terms of other automation of some of our activities and lines. We've got a fair number of levers in terms of how we do the lab work in a larger lab environment, which we can, which we're playing with. We also have optimization in terms of where we do the lab work as well, being in several different Länder. That helps us a little bit to work on that as well. I'd say we've got an ability, James, to mitigate, to maintain our margins for some time, for the next 18 months, 20-24 months, we can probably manage this. I expect we're gonna see some sort of change in that sort of time period in terms of pricing. That's great. Thank you. Then just a quick follow-up. I noticed the number of blood-drawing points as well, went down to about 840 from closer to 900. Are we there, or is that a sort of another sort of an area which, you know, we could potentially see some further rationalization to help maintain profitability? No, in the underlying business areas, we've increased, James. We disposed of the Belarusian business, which had a number of units. Okay. What you're seeing there is the impact of that. In our other markets, we've been adding new units. Okay. Okay. Added nine in first quarter and another nine or so in second quarter. We continue to develop those. There's nothing unusual there. We also had a comment where we talked about the German reforms to the German hospital activities. This is not about the lab work. This is about the wider reforms in the German healthcare system, aimed at where the hospital work can be done. I think that that's a sort of long overdue reform in the hospital sector, which will impact the total cost of delivering healthcare in Germany, which will then be positive in terms of being more efficient in terms of the total overall funding for Germany. That's, I think, quite an important reform. Doesn't impact us directly, but can have a positive impact on the overall healthcare system in Germany. That's great. Thank you. Thank you for your question. There's no more questions in the queue at the moment. I would now like to hand you over to your speaker, Fredrik Rågmark. All right. Well, thank you all for taking the time to listen and for asking relevant questions. With that, we wrap up, and, if not before, we will speak to you after the third quarter. Thank you. Bye. Thank you. This concludes today's conference call. You may now disconnect.